ANDA 218742, held by Glenmark Speclt. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 218742 (Fluticasone Propionate), held by Glenmark Speclt, was first approved by FDA on Mar 16, 2026, with 0 approved supplements and 0 published complete response letters.
Uses Temporarily relieves these symptoms of hay fever or other upper respiratory allergies:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 16, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05MG/SPRAY · spray, metered;nasal | Fluticasone Propionate | OTC |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters